---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-023860"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:20:12.016201+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BriaPro subsidiary reports $317K net loss, $1 cash, going concern doubt

## Summary
- Net loss of $316,517 for nine months ended April 30, 2024; zero revenue.
- Cash and equivalents of $1; current liabilities $356,734; shareholders' deficit $301,924.
- Going concern warning: dependent on future financing, significant doubt.
- Intangible assets (patents) of $203,614 from August 2023 spin-out from BriaCell.
- Operating loss of $366,960 for the nine-month period, R&D expense $227,249.

## SEC filing metadata
- accession: 0001493152-24-023860
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224023860/0001493152-24-023860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224023860/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-023860
- JSON: https://secwatch.observer/filing/0001493152-24-023860.json
- Plain text: https://secwatch.observer/filing/0001493152-24-023860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.